Ireland
--:--IST
Priya Life Science Compound trial record
Compound · clinical trials

Prednisone/Prednisolone clinical trials

Also listed in trial records as Deltasone/Omnipred, Prednisone/Prenisolone
Source: ClinicalTrials.gov, U.S. National Library of Medicine — the 11 trials in our USA, Germany, UK, Spain, Italy, France, South Korea, Australia, Turkey, Brazil, Poland, Belgium, Taiwan, Canada, China, Japan, Czechia, Austria, Israel, Switzerland, Netherlands, Ireland, Singapore, India and Mexico registers that name Prednisone/Prednisolone as an intervention. Synced 9 Nov 2026
11Current trials
8Recruiting now
9Lead sponsors
25Country registers
At a glance

Prednisone/Prednisolone is named as an intervention in 11 current clinical trials in our USA, Germany, UK, Spain, Italy, France, South Korea, Australia, Turkey, Brazil, Poland, Belgium, Taiwan, Canada, China, Japan, Czechia, Austria, Israel, Switzerland, Netherlands, Ireland, Singapore, India and Mexico registers. 8 are recruiting patients now. The most common phase is Phase 3. The sponsor with the most trials is Regeneron Pharmaceuticals (3). The most-studied condition is Follicular Lymphoma (FL).

Patient leaflets for Prednisone/Prednisolone

The package leaflet is the official guide for patients that comes with every medicine. These links go to the regulators that publish it.

  • UK
    United Kingdom: Search MHRA Products
    Patient information leaflets and SmPCs for UK-licensed products.
  • US
    United States: Search DailyMed
    FDA-approved labels, including patient and medication guides.

Leaflets differ between brands and countries; always read the one that comes with your own medicine. This is regulatory information, not medical advice.

Trials by status

  • Recruiting873%
  • Active, closed327%

Trials by phase

  • Phase 3655%
  • Phase 2218%
  • Phase 1/219%
  • Phase 419%
  • Phase 119%
01

Clinical trials of Prednisone/Prednisolone

11 trials
StudyPhaseStatusLead sponsorRegisters
A Study to Investigate OCS Tapering in Adult Participants With Generalized Myasthenia Gravis Treated With Ravulizumab
NCT07221838 · Generalized Myasthenia Gravis, gMG
Phase 4 Recruiting Alexion Pharmaceuticals, Inc USA, Germany, Italy, Japan
A Trial to Learn if Odronextamab is Safe and Well-Tolerated and How Well it Works Compared to Rituximab Combined With Different Types of Chemotherapy for Adult Participants With Previously Untreated Follicular Lymphoma
NCT06091254 · Follicular Lymphoma (FL)
Phase 3 Recruiting Regeneron Pharmaceuticals UK, USA, Germany, France, Spain, Italy, Belgium, Poland, Switzerland, Austria, Czechia, Turkey, Canada, Brazil, South Korea, Taiwan, Australia, Israel
A Study to Compare How Well Odronextamab Combined With Chemotherapy Works and How Safe it is Against Rituximab Combined With Chemotherapy, in Adult Patients With Previously Untreated Diffuse Large B-cell Lymphoma
NCT06091865 · Diffuse Large B-cell Lymphoma (DLBCL)
Phase 3 Recruiting Regeneron Pharmaceuticals Ireland, UK, USA, Germany, France, Spain, Italy, Belgium, Poland, Austria, Czechia, Turkey, Brazil, South Korea, Taiwan, Singapore, Australia, Israel
A Study to Compare the Efficacy and Safety of Golcadomide in Combination With Rituximab (Golca + R) vs Investigator's Choice in Participants With Relapsed/Refractory Follicular Lymphoma Who Have Received at Least 1 Prior Line of Systemic Therapy (GOLSEEK-4)
NCT06911502 · Follicular Lymphoma
Phase 3 Recruiting Celgene UK, USA, India, China, Germany, France, Spain, Italy, Netherlands, Poland, Turkey, Canada, Brazil, Japan, South Korea, Australia
A Study of Pasritamig With Docetaxel Versus Docetaxel in Participants With Metastatic Castration-Resistant Prostate Cancer
NCT07225946 · Prostatic Neoplasms, Castration-Resistant
Phase 3 Recruiting Janssen Research & Development, LLC UK, USA, China, Germany, France, Spain, Italy, Belgium, Turkey, Canada, Brazil, Japan, South Korea, Taiwan, Australia
A Phase III Trial of BNT324 Versus Docetaxel in Metastatic Castration-resistant Prostate Cancer
NCT07365995 · Metastatic Castration-resistant Prostate Cancer
Phase 3 Recruiting BioNTech SE UK, USA, China, Germany, Belgium, Poland, Australia
Study of Dato-DXd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03)
NCT05489211 · Endometrial Cancer, Gastric Cancer, Metastatic Castration-resistant Prostate Cancer
Phase 2 Recruiting AstraZeneca UK, USA, China, Germany, France, Spain, Italy, Poland, Switzerland, Turkey, Canada, Japan, South Korea, Taiwan
TulmiSTAR-02: A Phase I/II Open-label Study of Tulmimetostat in Combination With Darolutamide vs. Darolutamide, and Tulmimetostat With Abiraterone in Patients With Metastatic Hormone-sensitive Prostate Cancer (mHSPC)
NCT07190300 · Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)
Phase 1/2 Recruiting Novartis Pharmaceuticals UK, USA, China, Germany, France, Spain, Italy, Turkey, Canada, Brazil, South Korea, Australia
A Trial to Learn if Odronextamab Combined With Chemotherapy is Safe and Well-Tolerated and How Well it Works Compared to Rituximab Combined With Chemotherapy for Adult Participants With Follicular Lymphoma
NCT06097364 · Follicular Lymphoma (FL)
Phase 3 Active, closed Regeneron Pharmaceuticals UK, USA, Germany, France, Spain, Italy, Belgium, Poland, Austria, Czechia, Turkey, Brazil, Taiwan, Australia, Israel
Safety and Efficacy of Pembrolizumab (MK-3475) in Children and Young Adults With Classical Hodgkin Lymphoma (MK-3475-667/KEYNOTE-667)
NCT03407144 · Hodgkin Lymphoma
Phase 2 Active, closed Merck Sharp & Dohme LLC UK, USA, Germany, France, Spain, Italy, Netherlands, Czechia, Brazil, Mexico, South Korea
M9466 Alone or in Combination in Advanced Solid Tumors (DDriver 501)
NCT06421935 · Advanced Solid Tumor
Phase 1 Active, closed EMD Serono Research & Development Institute, Inc USA, Spain, Japan, South Korea, Australia

Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.

02

Conditions studied with Prednisone/Prednisolone

13 conditions
All 13 conditions
Condition (as registered)Trials
Follicular Lymphoma (FL)2
Metastatic Castration-resistant Prostate Cancer2
Diffuse Large B-cell Lymphoma (DLBCL)1
Follicular Lymphoma1
Hodgkin Lymphoma1
Prostatic Neoplasms, Castration-Resistant1
Endometrial Cancer1
Gastric Cancer1
Ovarian Cancer1
Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)1
Generalized Myasthenia Gravis1
gMG1
Advanced Solid Tumor1
05

Related compounds

06

Questions about Prednisone/Prednisolone trials

How many clinical trials are testing Prednisone/Prednisolone?

11 current trials in our USA, Germany, UK, Spain, Italy, France, South Korea, Australia, Turkey, Brazil, Poland, Belgium, Taiwan, Canada, China, Japan, Czechia, Austria, Israel, Switzerland, Netherlands, Ireland, Singapore, India and Mexico registers name Prednisone/Prednisolone as a drug or biological intervention, as of the registry sync on 9 November 2026. Completed and withdrawn studies are not counted.

Are Prednisone/Prednisolone trials recruiting patients?

Yes. 8 of the 11 trials are recruiting: 8 with sites in USA, 8 with sites in Germany, 7 with sites in UK, 6 with sites in Spain, 7 with sites in Italy, 6 with sites in France, 6 with sites in South Korea, 6 with sites in Australia, 6 with sites in Turkey, 5 with sites in Brazil, 5 with sites in Poland, 4 with sites in Belgium, 4 with sites in Taiwan, 5 with sites in Canada, 5 with sites in China, 4 with sites in Japan, 2 with sites in Czechia, 2 with sites in Austria, 2 with sites in Israel, 2 with sites in Switzerland, 1 with sites in Netherlands, 1 with sites in Ireland, 1 with sites in Singapore and 1 with sites in India. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.

Who sponsors Prednisone/Prednisolone clinical trials?

Regeneron Pharmaceuticals (3), Celgene (1), Merck Sharp & Dohme LLC (1) and Janssen Research & Development, LLC (1), among 9 lead sponsors in total. The number in brackets is how many trials each organisation leads.

Are there Prednisone/Prednisolone clinical trials in Ireland?

Yes. 1 trial in our Ireland register (ClinicalTrials.gov). Some may be the same study registered in both. See the Irish clinical trials register for sites and contacts.

Where does this information come from?

Every trial, status, phase and sponsor on this page is copied from public ClinicalTrials.gov records by a daily sync. Nothing here describes how Prednisone/Prednisolone works or whether it is effective, and it is not medical advice.

Approvals, shortages and trials, every Friday

One email a week with new EMA and FDA approvals, EU and US medicine shortages, how many trials are recruiting in Ireland, and the week's Irish pharma news.

Free. Unsubscribe from any email with one click. See our privacy policy.

How this page is built

Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how Prednisone/Prednisolone works or whether it is effective. Each trial links to its own record so you can check it yourself.

This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists Prednisone/Prednisolone (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 9 Nov 2026. How every register is built: methodology · fixes we have made: corrections log.

Please verify before you rely on this. This page is general information for life-science and pharmaceutical professionals. It is not medical advice, and it has not been reviewed by a clinician — our editorial team holds life-science qualifications, not clinical ones. It is not exhaustive and may not reflect the most recent label change. Always check the official prescribing information (US Prescribing Information or EU SmPC) and speak to your doctor or pharmacist before acting on anything here. Drugs in the same class are not automatically interchangeable, and approvals, brand names and indications differ between the US, the EU/Ireland (EMA/HPRA) and other regions. Spotted an error? Tell us — we correct promptly and log it.